Our Technology

GSN's proprietary technology is the first PGD technology to leverage data informatics to deliver highly accurate single cell testing for both aneuploidy and multiple disease-linked loci in parallel.

Since only a single copy of DNA is available from one cell, DNA measurements from conventional testing techniques are highly error-prone. This is a significant issue in the case of PGD where only one cell is available for analysis. The primary problem is allele dropout (ADO), defined as the failure to amplify one of the two gene copies (alleles) in a heterozygous cell. High ADO rates have caused PGD misdiagnoses.

Similarly, in the case of PGD for aneuploidy, current Florescent In Situ Hybridization (FISH) technology is limited, both in terms of diagnostic accuracy and the number of chromosomes that can be realistically and cost-effectively analyzed.

Our technology combines advanced informatics with data from the human genome project to reconstruct embryonic DNA with confidence exceeding 99%, thus neutralizing the issue of ADO and delivering highly accurate diagnostic results. Additionally, our technology can be simultaneously applied to aneuploidy screening for all 24 chromosomes, enabling reliable and affordable screening of multiple disease-linked genes and aneuploidy in parallel. GSN has a number of US patent filings covering this technology.